Exact Sciences is a leading global cancer diagnostics company, with more than 6,500 employees worldwide.

Exact Sciences’ workforce is located at 20 sites worldwide, with headquarters in Madison, Wisconsin. We have additional offices in Wisconsin, California, Arizona, Washington D.C., Utah, Massachusetts, Maryland, France, Italy, United Kingdom, Japan, Germany, and international headquarters in Switzerland.

Exact Sciences has 10 research & development centers and labs around the globe in Madison, WI; Marshfield, WI; Redwood City, CA; San Diego, CA; Phoenix, AZ; Baltimore, MD; Cambridge, MA; Oxford, UK; and Munich, Germany. The clinical laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP). The lab in Redwood City, CA is an ISO 15189:2012 internationally-recognized accredited laboratory for clinical testing.

In the U.S., Exact Sciences is certified under Fortune’s Great Place to Work® certified lists. In 2021, 88% of employee survey participants said Exact Sciences is a Great Place to Work® and 95% are proud to tell others they work for Exact Sciences.1

Exact Sciences’ 2021 revenue was $1.77 billion1.

Cologuard® is the first and only FDA-approved, non-invasive, multi-target, stool DNA-based colorectal cancer screening test. Since it was made available in 2014, Cologuard has helped screen more than 8 million people. For more information, visit www.cologuard.com.

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor to help optimize cancer treatment decisions. With more than 1.5 million patients tested in more than 90 countries1, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.exactsciencespo.com.

Note: tests are available in the United States. Availability outside of the U.S. differs by country.

The depth and breadth of the Exact Sciences’ pipeline is helping us provide several new cancer solutions to patients through the following innovative cancer diagnostics.

Estimated U.S. Total Addressable Market*:

- **$25B** multi-cancer screening
- **$18B** colorectal cancer screening
- **$15B** minimal residual disease & recurrence monitoring

Note: These tests have not been cleared or approved by the FDA and are not available for sale.

1. Internal Data on File. Exact Sciences Corporation. Madison, WI.
2. Turnaround time is based on qualified sample receipt.

*Exact Sciences estimates